GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maat Pharma SA (XPAR:MAAT) » Definitions » Beneish M-Score

Maat Pharma (XPAR:MAAT) Beneish M-Score : -1.89 (As of Jun. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Maat Pharma Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.89 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Maat Pharma's Beneish M-Score or its related term are showing as below:

XPAR:MAAT' s Beneish M-Score Range Over the Past 10 Years
Min: -1.89   Med: -1.76   Max: -1.63
Current: -1.89

During the past 6 years, the highest Beneish M-Score of Maat Pharma was -1.63. The lowest was -1.89. And the median was -1.76.


Maat Pharma Beneish M-Score Historical Data

The historical data trend for Maat Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maat Pharma Beneish M-Score Chart

Maat Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - - -1.63 -1.89

Maat Pharma Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -1.63 - -1.89

Competitive Comparison of Maat Pharma's Beneish M-Score

For the Biotechnology subindustry, Maat Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maat Pharma's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maat Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Maat Pharma's Beneish M-Score falls into.



Maat Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Maat Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9385+0.528 * 1.0271+0.404 * 1.124+0.892 * 1.558+0.115 * 3.5459
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9812+4.679 * -0.024388-0.327 * 1.3113
=-1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was €1.53 Mil.
Revenue was €2.23 Mil.
Gross Profit was €1.66 Mil.
Total Current Assets was €31.99 Mil.
Total Assets was €42.93 Mil.
Property, Plant and Equipment(Net PPE) was €9.17 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.87 Mil.
Selling, General, & Admin. Expense(SGA) was €3.00 Mil.
Total Current Liabilities was €11.52 Mil.
Long-Term Debt & Capital Lease Obligation was €10.62 Mil.
Net Income was €-19.72 Mil.
Gross Profit was €0.00 Mil.
Cash Flow from Operations was €-18.67 Mil.
Total Receivables was €1.05 Mil.
Revenue was €1.43 Mil.
Gross Profit was €1.09 Mil.
Total Current Assets was €42.12 Mil.
Total Assets was €44.73 Mil.
Property, Plant and Equipment(Net PPE) was €0.97 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.43 Mil.
Selling, General, & Admin. Expense(SGA) was €1.96 Mil.
Total Current Liabilities was €9.22 Mil.
Long-Term Debt & Capital Lease Obligation was €8.38 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.531 / 2.228) / (1.047 / 1.43)
=0.687163 / 0.732168
=0.9385

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.091 / 1.43) / (1.655 / 2.228)
=0.762937 / 0.742819
=1.0271

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (31.994 + 9.172) / 42.931) / (1 - (42.124 + 0.966) / 44.726)
=0.041112 / 0.036578
=1.124

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2.228 / 1.43
=1.558

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.429 / (0.429 + 0.966)) / (0.871 / (0.871 + 9.172))
=0.307527 / 0.086727
=3.5459

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3.001 / 2.228) / (1.963 / 1.43)
=1.346948 / 1.372727
=0.9812

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((10.62 + 11.522) / 42.931) / ((8.375 + 9.217) / 44.726)
=0.515758 / 0.393328
=1.3113

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-19.717 - 0 - -18.67) / 42.931
=-0.024388

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Maat Pharma has a M-score of -1.89 suggests that the company is unlikely to be a manipulator.


Maat Pharma Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Maat Pharma's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Maat Pharma (XPAR:MAAT) Business Description

Traded in Other Exchanges
Address
70 Avenue Tony Garnier, Lyon, FRA, 69007
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.

Maat Pharma (XPAR:MAAT) Headlines

No Headlines